Indoco Remedies Limited has informed the Exchange about Transcript

Indoco Remedies reported its first positive quarter after six quarters of losses. Standalone Q4 revenue grew 25.8% YoY to INR 4,291 million, with standalone EBITDA margin recovering sharply to 14.7% from just 1% in the year-ago quarter, driven by a 94.6% surge in international formulations (US +77.5%, Europe +68.7%, emerging markets +134%). The domestic business was muted due to a poor seasonal quarter, particularly in anti-infectives and respiratory. The company hived off its India and Africa ophthalmic business to Sunway to focus on core ethical brands. Working capital pressures persist: receivables grew disproportionately due to long credit periods in emerging markets, MSME payables were overdue (management expects settlement within a week), and total consolidated debt stands at INR 960 crore with scheduled repayments of INR 140 crore annually. Forex loss of INR 24 crore on an ECB loan impacted consolidated interest costs. Warren Remedies and FPP continue to drag on consolidated profitability due to API validation cycles and high operating expenses. Management guided on continued margin improvement in regulated markets going forward as MMP scale-ups complete and new product launches (liquid orals) contribute.